Home >> Report Store >> Healthcare >> Cancer Therapeutics Market Analysis Size, Share & Industry Report, 2025 >

Cancer Therapeutics Market Size Worth $186.3 Billion By 2025 | CAGR: 10.0%

Published Date : 28 / 07 / 18 | Report Format: PDF

The global cancer therapeutics market is expected to grow at growth rate of 10.0% to reach USD 186.3 billion by 2025.

Cancer is characterized by the abnormal proliferation of cells beyond their usual boundaries. This disease is one of the most prevalent chronic conditions, affecting millions of population worldwide every year. For example, as per the World Health Organization (WHO), more than 9.6 million patients died due to cancer in 2018 across the globe. The organization has also mentioned that the number of new cancer cases is projected to rise by 70% over the next 2 decades. Due to constant rising in cancer incidences, research activities to develop new and effective therapeutics has increased significantly. It is justified by the sharp increase in the number of pipeline therapeutics. According to an article published by the American Cancer Society (2017), the pipeline of oncology drugs has expanded by 60% during the past decade.

In addition, favorable government initiatives would, in turn, support the industry growth significantly. For example, Conference Series Ltd. is engaged in organizing numerous Oncology & Cancer Conferences. This organization has hosted more than 600 conferences, 1200 symposiums, and 1200 plus workshops on cancer-related topics. However, challenges encountered during the clinical trials for developing cancer therapeutics is expected to hamper the industry growth to some extent.

Key Takeaways

  • Of the different types, blood and breast cancers are accounted for the majority of revenue share. Increasing incidences of these cancers drive the segment growth. According to the Leukemia & Lymphoma Society (LLS), every three minutes, one person is diagnosed with a blood cancer in the U.S.
  • However, prostate cancer is anticipated to grow with the fastest CAGR of 12.6% during the forecast period. Advancements in proteomic technologies coupled with improvements in screening and diagnosis techniques will support the segment growth.
  • Chemotherapy accounted for the highest revenue share, accounted for more than 45% share throughout the study period. Its potential molecular genetics assessment, low side effects and proven efficacy back up the growth.
  • Agents like alkylating agents, anti-metabolites, and anti-microtubule agent are commonly used for the chemotherapy treatment
  • We analyzed that by 2020, most of the oncology drugs will be available for multiple indications. A new wave of cancer therapy is sweeping the industry landscape and offering excitement and hope among cancer drug manufacturers.
  • Lots of efforts are made by many researchers to develop cancer therapeutics for multiple indications. For example, of 88 cancer therapeutics marketed in 2014, approximately 40 were for single indications and more than 48 were for multiple indications. This new strategy, would, in turn, amplify the need for end-users.
  • North America accounted for significant revenue share due to a continuous increase in the patient numbers in the U.S. As per the National Cancer Institute (NCI), in 2016, around 1,685,000 new cancer cases were recorded in the U.S. and 595,690 patients died from the disease.
  • In addition, a launch of novel therapeutics such as Xtandi (enzalutamide), Zytiga (abiraterone acetate) and Xofigo set a healthy platform for the regional growth and development
  • This fragmented industry is characterized by the presence of a large number of small scale and large scale players. F. Hoffmann-La Roche emerged as a key player, contributing 17.03% share of the global market owing to the strong performance of company’s blockbuster drug Avastin and Herceptin. In 2015, the company registered USD 6,631.6 and USD 6,486.7 from Avastin and Herceptin respectively.
  • Whereas, companies namely Novartis, Amgen, Inc., Johnson and Johnson, and Eli Lilly and Company captured significant market share. New product launch and strategic collaborations helped these players to sustain their market position
  • In April 2018, Eli Lilly and Company announced positive phase III result of Cyramza (Ramucirumab) for the treatment of patients with hepatocellular carcinoma (HCC), a type of liver cancer.


  • Understanding of the strategies that are being adopted by the key players in this market to stay competitive
  • Extensive analysis of the key players dominating the competitive landscape of this market
  • In-depth analysis of the key factors are propelling the growth of the global market
  • Detailed analysis of the geographic region that will witness the strongest growth
  • Granular analysis of the current market scenario and the expected market grow

The scope of this report covers the market by its major segments, which include as follows:

Market Segmentation


  • Prostate Cancer
  • Blood Cancer
  • Lung Cancer
  • Skin Cancer
  • Gastrointestinal Cancer
  • Breast Cancer
  • Others


  • Chemotherapy
  • Hormonal
  • Immunotherapy
  • Targeted Therapy
  • Others


  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Rest of APAC
  • Rest of the World
    • Middle East and Africa
    • Latin America

Why AnalystView?



Trusted Partnership

We strive to become one of the trusted partner of our client by offering value added services and concrete research data.


Tailor Made Solutions

From single reports and data downloads to enterprise subscriptions to custom consultancy, we can base our precise solutions round our client’s exact needs.

Turnaround Time

Our analyst aims to provide research studies in quickest turnaround time and in a much cost effective manner.


Data Accuracy And Reliability

We utilize a mix of primary, secondary research, and machine learning algorithms to generate accurate and comprehensive data about market size and revenue forecasts.

Competitive Pricing

We offer most competitive pricing policy across the research industry

Client Testimonials


Asia Pacific based Chemical Industry (Privacy Requested)

Thanks AnalystView for putting a great team to work on our research projects. It was a smooth transition of knowledge and delivery was seamless. We are keen to work with you on our upcoming projects. Thank you once again for the professional attitude your team has demonstrated.

CEO, Europe based Digital Media Company (Privacy Requested)

We had confusion after receiving the final data sheet of report. As per some preliminary we already have, we believe the market is over estimated.. However, after string of calls with analyst, we found their final research analysis was methodologically sound and their work to be very professional and up […]

Managing Director, Chemical based Company, Asia Pacific (Privacy Requested)

We are happy with the way the AnalystView member understood the brief and went about executing our research project.

U.S. Headquartered Medical Device Company (Privacy Requested)

AnalystView team has done brand assessment study for blood glucose monitoring devices market, in which we want enter into….We were very impressed not only by their research skills but also by their understanding of issues relevant to our requirements…!!

Vice President, Petrochemical Firm based in China (Privacy Requested)

It was a pleasure assigning project to AnalystView; they are reliable, fast and friendly. Highly recommend this company for research workJGood stuff!

US based healthcare service provider (Privacy Requested)

Frankly, we didn’t expect much comprehensive data for the report we purchased. To be surprised, I must say the report we received was very nicely executed….It contains all the information we are looking for and satisfied with the quality of the report. Thank you team

Europe based Chemical Industry (Privacy Requested)

Just wanted to say massive thanks for all the help from the AnalystView team. We purchased two reports one is Food Safety Testing report and another one is Enzyme market. These reports have helped us build a sound knowledge base of our business segments and have taken our business to […]

Why Choose Us


We devise research report with quality data:

Combined with an in-depth knowledge of the current industry and a sharp analytical mind, AnalystView serve our customer accurate research in accordance with a constantly evolving industry.

We work with businesses just like yours: 

AnalystView committed to making a positive difference for our clients. This means whatever you demand, chances are we already have experience something similar.

Share This